AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms
October 21, 2026 · 7:00 AM · MENLO PARK, Calif.
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced the presentation of a poster detailing the design of its planned Phase 2 clinical trial evaluating epetraborole in patients with polycythemia vera (PV) at the 18th International Congress on Myeloproliferative Neoplasms being held October 29-30...
- PublishedOctober 21, 2026 · 7:00 AM
- LocationMENLO PARK, Calif.
- IndustryScience
- LanguageEN
Published by Business Wire. Read the original announcement for the full release.
Read the full announcement →